全文获取类型
收费全文 | 47786篇 |
免费 | 3700篇 |
国内免费 | 531篇 |
专业分类
耳鼻咽喉 | 240篇 |
儿科学 | 733篇 |
妇产科学 | 854篇 |
基础医学 | 1501篇 |
口腔科学 | 659篇 |
临床医学 | 10125篇 |
内科学 | 3924篇 |
皮肤病学 | 284篇 |
神经病学 | 1091篇 |
特种医学 | 658篇 |
外国民族医学 | 1篇 |
外科学 | 4680篇 |
综合类 | 7530篇 |
现状与发展 | 3篇 |
一般理论 | 3篇 |
预防医学 | 12352篇 |
眼科学 | 261篇 |
药学 | 4982篇 |
127篇 | |
中国医学 | 887篇 |
肿瘤学 | 1122篇 |
出版年
2024年 | 49篇 |
2023年 | 980篇 |
2022年 | 1657篇 |
2021年 | 2536篇 |
2020年 | 3007篇 |
2019年 | 1943篇 |
2018年 | 1824篇 |
2017年 | 1873篇 |
2016年 | 1943篇 |
2015年 | 1885篇 |
2014年 | 4512篇 |
2013年 | 4040篇 |
2012年 | 3567篇 |
2011年 | 3567篇 |
2010年 | 2953篇 |
2009年 | 2448篇 |
2008年 | 2382篇 |
2007年 | 2083篇 |
2006年 | 1876篇 |
2005年 | 1402篇 |
2004年 | 1198篇 |
2003年 | 931篇 |
2002年 | 636篇 |
2001年 | 475篇 |
2000年 | 402篇 |
1999年 | 309篇 |
1998年 | 284篇 |
1997年 | 219篇 |
1996年 | 176篇 |
1995年 | 121篇 |
1994年 | 110篇 |
1993年 | 108篇 |
1992年 | 74篇 |
1991年 | 79篇 |
1990年 | 44篇 |
1989年 | 42篇 |
1988年 | 33篇 |
1987年 | 29篇 |
1986年 | 29篇 |
1985年 | 48篇 |
1984年 | 30篇 |
1983年 | 28篇 |
1982年 | 18篇 |
1981年 | 21篇 |
1980年 | 16篇 |
1979年 | 8篇 |
1978年 | 9篇 |
1977年 | 3篇 |
1976年 | 3篇 |
1974年 | 6篇 |
排序方式: 共有10000条查询结果,搜索用时 17 毫秒
61.
《Gaceta sanitaria / S.E.S.P.A.S》2022,36(3):278-282
Continuous management improvement should be an aspiration for all public sector organizations. External comparison or benchmarking identifies good practices in similar organizations. For public health services, it is not easy to obtain such indicators. The objectives of this paper are to describe the process of conducting a benchmarking exercise for a public health agency, and to share its results. For this purpose, agencies that may be compared were identified, and their websites were searched for annual reports or other documents with indicators of the activities or results of public health services. Limitations and contextual aspects of the indicators of the different organizations were identified, as well as ways to improve their comparability. Finally, a set of 19 indicators is proposed, as an initial core for quality management comparisons. 相似文献
62.
目的:探析2型糖尿病患者采取参芪降糖颗粒联合二甲双胍进行治疗的降糖效果。方法:选取2016年1月至2019年10月马鞍山市中心医院收治的2型糖尿病患者66例作为研究对象,按照随机数字表法分为对照组与观察组,每组33例,对照组通过二甲双胍进行治疗,观察组通过二甲双胍联合参芪降糖颗粒进行治疗,比较2组患者治疗总有效率、血糖参数、不良反应发生率等指标。结果:对照组、观察组的治疗总有效分别为75.76%、93.94%,与对照组比较,观察组的治疗总有效率明显较高(P<0.05);观察组的空腹血糖、餐后2 h血糖等血糖参数在治疗后明显低于对照组患者(P<0.05);对照组、观察组的治疗不良反应发生率分别为21.21%、3.03%,观察组治疗不良反应发生率明显低于对照组(P<0.05)。结论:2型糖尿病患者采取参芪降糖颗粒联合二甲双胍进行治疗能够获得较为理想的效果,可明显改善血糖指标,安全性较高,对改善患者的治疗预后有着促进的作用。 相似文献
63.
64.
65.
目的调查呼吸专科护士慢性呼吸疾病管理现状,为提高慢性呼吸疾病的管理水平提供参考。方法依据《中国成人慢性呼吸疾病患者护理管理指南》设计调查问卷,对重庆、四川、贵州、陕西、河北、湖北、海南7省市的205名呼吸专科护士进行问卷调查。结果呼吸专科护士慢性呼吸疾病管理总分为(140.72±23.90)分。慢性呼吸疾病管理得分最低的3个条目有评估工具应用、个性化管理计划的实施、慢阻肺随访的次数及指导哮喘患者使用峰流速仪;呼吸专科护士所在单位慢性呼吸疾病管理平台建设均低于50%。结论呼吸专科护士慢性呼吸疾病管理处于中等偏下水平,评估是慢性呼吸疾病管理的薄弱点。需加强呼吸专科护士专业能力培养,规范慢性呼吸疾病全程管理,强化医院平台建设等,提高慢性呼吸疾病的管理水平。 相似文献
66.
目的应用6σ理论对肿瘤标志物项目的分析性能进行评价,并初步确定各项目的质量目标。
方法收集本实验室2018年1至12月室内质控数据和国家卫生健康委临床检验中心室间质量评价结果,以生物学变异导出的质量规范和国家室间质量评价标准作为允许总误差(TEa)计算6项肿瘤标志物的σ水平,并依据质量目标选择流程图和肿瘤标志物分析性能验证图评价肿瘤标志物的分析性能,进而为肿瘤标志物选择合适的质量目标。
结果应用不同层级的生物学变异导出的质量规范和国家室间质量评价标准,肿瘤标志物项目的σ水平存在显著差异;依据质量目标选择流程图:选择生物学变异导出的"适当的"质量规范作为CA125项目的质量目标,选择生物学变异导出的"最低的"质量规范作为t-PSA、CEA、AFP、CA199和CA153项目的质量目标。
结论6σ能够客观评价肿瘤标志物的分析性能,并为实验室质量目标的选择提供重要的参考价值。 相似文献
67.
Fiene Marie Kuijper Uma V. Mahajan Seul Ku Daniel A.N. Barbosa Sheila M. Alessi Sherman C. Stein Kyle M. Kampman Brandon S. Bentzley Casey H. Halpern 《Neuromodulation》2022,25(2):253-262
ObjectivesCocaine is the second most frequently used illicit drug worldwide (after cannabis), and cocaine use disorder (CUD)-related deaths increased globally by 80% from 1990 to 2013. There is yet to be a regulatory-approved treatment. Emerging preclinical evidence indicates that deep brain stimulation (DBS) of the nucleus accumbens may be a therapeutic option. Prior to expanding the costly investigation of DBS for treatment of CUD, it is important to ensure societal cost-effectiveness.AimsWe conducted a threshold and cost-effectiveness analysis to determine the success rate at which DBS would be equivalent to contingency management (CM), recently identified as the most efficacious therapy for treatments of CUDs.Materials and MethodsQuality of life, efficacy, and safety parameters for CM were obtained from previous literature. Costs were calculated from a societal perspective. Our model predicted the utility benefit based on quality-adjusted life-years (QALYs) and incremental-cost-effectiveness ratio resulting from two treatments on a one-, two-, and five-year timeline.ResultsOn a one-year timeline, DBS would need to impart a success rate (ie, cocaine free) of 70% for it to yield the same utility benefit (0.492 QALYs per year) as CM. At no success rate would DBS be more cost-effective (incremental-cost-effectiveness ratio <$50,000) than CM during the first year. Nevertheless, as DBS costs are front loaded, DBS would need to achieve success rates of 74% and 51% for its cost-effectiveness to exceed that of CM over a two- and five-year period, respectively.ConclusionsWe find DBS would not be cost-effective in the short term (one year) but may be cost-effective in longer timelines. Since DBS holds promise to potentially be a cost-effective treatment for CUDs, future randomized controlled trials should be performed to assess its efficacy. 相似文献
68.
《Vaccine》2016,34(38):4635-4641
BackgroundBroad use of monovalent Haemophilus influenzae type b (Hib) conjugate vaccines based on the capsular polysaccharide polyribosyl-ribitol phosphate (PRP), has significantly reduced invasive Hib disease burden in children worldwide, particularly in children aged <1 year. In Japan, PRP conjugated to tetanus toxoid (PRP-T) vaccine has been widely used since the initiation of public funding programs followed by a routine vaccination designation in 2013.MethodsWe compared the immunogenicity and safety of PRP conjugated to a non-toxic diphtheria toxin mutant (PRP-CRM197) vaccine with the PRP-T vaccine when administered subcutaneously to healthy Japanese children in a phase III study. Additionally, we evaluated the immunogenicity and safety profiles of a diphtheria–tetanus acellular pertussis (DTaP) combination vaccine when concomitantly administered with either PRP-CRM197 or PRP-T vaccines. The primary endpoint was the “long-term seroprotection rate”, defined as the group proportion with anti-PRP antibody titers ⩾1.0 μg/mL, after the primary series.ResultsLong-term seroprotection rates were 99.3% in the PRP-CRM197 group and 95.6% in the PRP-T group. The intergroup difference (PRP-CRM197 group – PRP-T group) was 3.7% (95% confidence interval: 0.099–7.336), demonstrating that PRP-CRM197 vaccine was non-inferior to PRP-T vaccine (p < 0.0001). Furthermore, the “short-term seroprotection rate” (anti-PRP antibody titer ⩾0.15 μg/mL) before booster vaccination was higher in the PRP-CRM197 group than in PRP-T. Concomitant administration of PRP-CRM197 vaccine with DTaP vaccine showed no differences in terms of immunogenicity compared with concomitant vaccination with PRP-T vaccine and DTaP vaccine. Although CRM197 vaccine had higher local reactogenicity, overall, both Hib vaccines had acceptable safety and tolerability profiles.ConclusionThe immunogenicity of PRP-CRM197 vaccine administered subcutaneously as a three-dose primary series in children followed by a booster vaccination 1 year after the primary series induced protective levels of Hib antibodies with no safety or tolerability concerns.Clinical trial registry: Registered on ClinicalTrials.gov: NCT01379846 相似文献
69.
70.
《The surgeon》2020,18(3):165-177
IntroductionThe liver is the most frequently damaged organ in blunt abdominal trauma. It is widely accepted that hemodynamically stable patients with low-grade liver trauma should be treated with non-operative management, however there is controversy surrounding its safety and efficacy in high-grade trauma. The purpose of this review is to investigate the role of non-operative management in patients with high-grade liver trauma.MethodsPubMed and reference lists of PubMed articles were searched to find studies that examined the efficacy of non-operative management in high-grade liver injury patients, and compare it to operative management. Non-operative management was considered successful if rescue surgery was avoided. Outcomes considered were success, mortality, and complication rates.ResultsThe electronic search revealed 2662 records, 8 of which met the inclusion criteria. All 8 studies contained results suggesting that non-operative management was safe and effective in hemodynamically stable patients with high-grade liver trauma. By combining the outcomes of the different studies, non-operative management had a high success rate of 92.4% (194/210) in high-grade liver trauma patients, which was near the overall 95.0% non-operative management success rate. Non-operative management also had mortality and complication rates of 4.6% (9/194) and 9.7% (7/72) in high-grade injury patients, respectively, compared to operative management's 17.6% (26/148) and 45.5% (5/11).ConclusionNon-operative management of liver trauma is safe and effective in hemodynamically stable patients with high-grade liver injury. It is associated with significantly lower mortality compared with operative management. More studies are required to evaluate complications of non-operative management in high-grade liver injury. 相似文献